Company intelligence / Profile preview

PsychoGenics

Ownership: Private
Employees: ~120
Development stage: Preclinical

Overview

PsychoGenics has pioneered AI-driven phenotypic screening for neuropsychiatric drug discovery. Its SmartCube platform has led to the identification of several novel compounds now in clinical development with partners such as Sunovion and Roche. Notably, SEP‑363856 (“ulotaront”) is in Phase 3 trials for schizophrenia. The company also maintains an internal pipeline targeting agitation and treatment-resistant depression entering IND-enabling studies

Therapeutic areas: PsychiatryNeurology
Modalities: Small molecule
Industry: Biotech

Drug pipeline

2 assets

RO7117997

Preclinical

1 more asset in the full pipeline.

Request access →

Partnerships

Sunovion PharmaceuticalsRocheKaruna TherapeuticsBlue Oak Pharmaceuticals

Beyond the preview

Go deeper on PsychoGenics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PsychoGenics.

Explore the full profile